Compare KraneShares CSI China Internet ETF (KWEB) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares CSI China Internet ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? KraneShares CSI China Internet ETF trades at $24.13 (market cap $4.51B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares CSI China Internet ETF for 59 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| KWEB | SYRE | |
|---|---|---|
Market Cap | $4.51B | $7.52B |
Volume | 12,272,723 | 1,441,031 |
Sector | Sector/Thematic | Health |
52-Week High | $41.35 | $108.92 |
52-Week Low | $23.63 | $22.18 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KWEB trades at $24.72, down 0.12% with neutral technical signals. The ETF faces mixed institutional activity amid ongoing U.S.-China trade dynamics. Recent news highlights China's economic challenges including industrial overcapacity and trade rebalancing pressures, while corporate profits showed a 26% Q2 surge according to Zacks Investment Research on September 8, 2026.
The outlook remains cautious due to geopolitical tensions and China's economic headwinds. Investment opportunity exists if U.S.-China relations improve, but risks include trade protectionism and domestic consumption weakness. Technical indicators suggest limited near-term momentum with key support at $25.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
